In addition, this inhibitor showed promise for the treatment of MYC-amplified NB, evinced by apoptosis induction in vitro and dose-dependent growth inhibition in PDX, with improved survival and tumor regression in 86% of patients 7 days of treatment initiation [889]. The gene discussed is MYC; the disease is neuroblastoma.